A phase II trial found no primary outcome success but suggests potential anxiolytic benefits of cannabidiol (CBD) with a strong safety profile in women with advanced breast cancer before tumor scans.
By Dr. Liji Thomas, MDReviewed by Danielle Ellis, B.Sc.Dec 18 2024 Phase II trial finds no primary outcome success but suggests potential anxiolytic benefits with a strong safety profile
Some research suggests that CBD safely reduces anxiety levels without adverse effects on mental or neurological health. However, few of these studies dealt with cancer patients, motivating the current study. They were randomized into two arms, one receiving CBD and the other placebo before a scan for tumor assessment.
The primary aim of the study was to compare the change in anxiety scores within 48 hours before a cancer scan, before and after taking the drug or the placebo. A secondary analysis independently assessed anxiety levels before vs. after ingestion in either arm, changes in other components of the VAMS scale, and drug safety.
The current study, in contrast, focused specifically on anxiety caused by a specific stimulus. No other cannabinoids or benzodiazepines were allowed during the day of the study. The CBD used was of regulatory-grade quality, so its use could be rapidly expanded if the results showed efficacy and were validated.
There was only a moderate correlation between the ‘afraid’ scores just before and after ingestion, at 30%. This, too, may have contributed to the lack of significant change in anxiety. If the study had excluded those with mild anxiety, the impact of CBD ingestion might have been better observed.
CANNABIS ANXIETY CANCER BREAST CANCER PHARMACOLOGY
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bovine H5N1 influenza shows potential for human adaptation through key mutationsRecent study reveals H5N1 mutations enhancing human receptor binding, highlighting pandemic risks and the need for vigilant surveillance of influenza strains.
Read more »
Potential new treatment for motor neurone disease shows promising resultsA potential new treatment for motor neurone disease (MND) developed by a company spun-out of The University of Queensland has produced successful results in a human clinical trial.
Read more »
Calibre discovers new opportunities at ValentineDrilling program at Valentine shows potential beyond the known resources
Read more »
Northern Ireland Shows Make New York Times Best TV Shows of 2024 ListTwo productions set in Northern Ireland, Say Nothing and Blue Lights, have been recognized by the New York Times in their Best TV Shows of 2024 list. Say Nothing, based on Patrick Radden Keefe's book, is noted for its enthralling narrative set during The Troubles, while Belfast-based Blue Lights features in the Best International Shows section.
Read more »
Two NI based shows feature in New York Times Best TV Shows 2024 listThe popular shows have been praised as 'enthralling' and 'terrific' while tackling serious subjects
Read more »
Trying a mushroom-powered Herbar facial at the world’s first CBD and adaptogenic spaMary Cleary is a writer based in London and New York. Previously beauty & grooming editor at Wallpaper*, she is now a contributing editor, alongside writing for various publications on all aspects of culture.
Read more »